Juvenile Idiopathic Arthritis

Nov 05, 2024

Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for the treatment of a...

Aug 16, 2022

Novartis’ Canakinumab Fails in Phase III Trials for NSCLC Canakinumab's prospects as an anticancer therapy were already dwindling when a third phase III trial in non-small cell lung cancer (NSCLC) failed to reach its objectives. The most recent setback came from the CANOPY-A study, which included patients with N...

Jul 19, 2019

Juvenile Idiopathic Arthritis (JIA) is an inflammation in the synovial membranes and the most chronic rheumatoid disorder in children and adolescents. The aim of Juvenile idiopathic arthritis treatment is to control pain; to preserve the range of motion (ROM), muscle strength, and function, manage systemic complica...

Jul 19, 2019

Juvenile Idiopathic Arthritis July is Juvenile Idiopathic Arthritis Awareness Month, which is dedicated to making everyone aware of arthritis. The most prevalent form of juvenile arthritis is juvenile idiopathic arthritis (JIA). Diagnosis of juvenile idiopathic arthritis can be difficult as joint pain ca...

Jul 15, 2019

1 in 3 people ageing from 18 to 64 has some type of arthritis as per recent estimates by Arthritis Foundation. There exist more than 100 types of Arthritis, and Juvenile Idiopathic Arthritis (JIA) is the most common form of rheumatic arthritis prevalent in children. JIA is a collective term for all the form forms o...